Please wait

Slide 1

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

Slide 2

 

Slide 3

Engineering the Alpha Advantage in Targeted Oncology

Slide 4

Unlocking New Treatment Options Across Solid Tumors:

Slide 5

Optimizing the Entire System

Slide 6

Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals

Slide 7

Optimizing Structural Chemistry:

Slide 8

Choosing The Right Isotope

Slide 9

Not All ²¹²Pb Programs Are Created Equal

Slide 10

 

Slide 11

Advancing a Theranostic Approach:

Slide 12

Solid Tumors are an Attractive Market for Radiopharmaceuticals

Slide 13

Expanding the Addressable Market

Slide 14

Direct-to-Hospital Delivery through Integrated Isotope Production

Slide 15

Daily Production at Regional Sites Ensures Supply of Ready-to-Administer Product

Slide 16

Reaching the Largest Addressable Market with Regional Manufacturing

Slide 17

Advancing a Diverse 212Pb-Based Oncology Portfolio

Slide 18

SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need

Slide 19

VMT-⍺-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2

Slide 20

Ongoing Phase 1/2a to Establish Broad Therapeutic Window for VMT-⍺-NET in NETs

Slide 21

VMT-⍺-NET: Baseline Patient Characteristics in ASCO 2026 Data Analysis

Slide 22

Patient Exposure and Follow-up with [212Pb]VMT-α-NET in ASCO 2026 Data Analysis

Slide 23

VMT-α-NET Best Response Deepens Over Time

Slide 24

VMT-α-NET Responses Deepen Over Time

Slide 25

VMT-⍺-NET: Durable Disease Control Across All Doses

Slide 26

Spider Plot of Tumor Change Over Time by Patient

Slide 27

Best-in-class Safety Profile1

Slide 28

Blood Creatinine During Follow-up for All Patients Treated (n=68)

Slide 29

VMT-α-NET’s Compelling Profile Supports Potential Registration Study at Current Dose Level

Slide 30

Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind

Slide 31

VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma

Slide 32

Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma

Slide 33

Preliminary Anti-tumor Activity Observed at 3.0 mCi Dose of VMT01

Slide 34

Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 10% of Patients)

Slide 35

VMT01 is Well-tolerated with Initial Anti-tumor Activity Supporting Further Development

Slide 36

FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential

Slide 37

PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors

Slide 38

Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors

Slide 39

PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent

Slide 40

Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain

Slide 41

 

Slide 42

A Decade of Deliberate, End-to-End Engineering

Slide 43

Built Over a Decade:

Slide 44

 

Slide 45

Abbreviations

Slide 46

APPENDIX

Slide 47

 

Slide 48

NETs Trials

Slide 49

Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment

Slide 50

Refractory Metastatic Melanoma Trials

Slide 51

ICI Combo Rationale: Strong Synergy with [212Pb]VMT01 in Melanoma

Slide 52

Metastatic Melanoma: Confirmed Partial Response after 2 Cycles of [212Pb]VMT01

Slide 53

Perspective’s CCK2R81 in Medullary Thyroid Cancer Compared to FDG and Fluorodopa

Slide 54

 

Slide 55

 

Slide 56

Construct designed for better clinical outcome

Slide 57

212Pb Uniquely Suited for Combination with Immune Check Point Inhibitors

Slide 58

Kinetics Matter: 212Pb Hits Hard and Fast for Strong Activity with Less Systemic Exposure

Slide 59

 

Slide 60